Remix Therapeutics is a clinical-stage biopharmaceutical company that has pioneered a new class of small molecule medicines targeting the RNA splicing machinery – correcting the disease-causing errors that drive cancers and other serious conditions at their source. Wednesday, October 21, 2026 10am EDT| Beyond the Protocol: Advancing Patient- and Caregiver-Centered Approaches in Neurodegenerative Clinical Trials ... Remix Therapeutics is a clinical-stage biopharmaceutical company that has pioneered a new class of small molecule medicines targeting the RNA splicing machinery - correcting the disease-causing errors that drive cancers and other serious conditions at their source. REM-422 is our lead program currently focused on developing a therapy for Adenoid Cystic Carcinoma (ACC), a rare cancer for which there is no approved therapy. Proven track record of successfully managing full-service data management CROs and external vendors for complex or multi-center clinical trials. Deep oncology or rare disease trial experience preferred. Trial Lifecycle Leadership: Lead data management activities from initial protocol review and study start-up through database cleaning, lock, and archival. Data Integrity & Review: Conduct ongoing data reviews via data listings and visualization tools to identify data anomalies, trends, and systemic risks across clinical programs. Study Team Representation: Serve as the primary Data Management representative on Trial Management Teams. Stakeholder Alignment: Actively partner with Biostatistics, Statistical Programming, Clinical Operations, Medical Writing, and Regulatory Affairs to ensure data management timelines align seamlessly with broader corporate objectives.

Original title: “Associate Director, Clinical Data Management - Xtalks”